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COVID-19 in patients undergoing chronic
kidney replacement therapy and kidney
transplant recipients in Scotland: findings
and experience from the Scottish renal
registry
Samira Bell1,2* , Jacqueline Campbell2, Jackie McDonald2, Martin O’Neill2, Chrissie Watters2, Katharine Buck3,
Zoe Cousland4, Mark Findlay5, Nazir I. Lone6, Wendy Metcalfe7, Shona Methven8, Robert Peel9, Alison Almond10,
Vinod Sanu11, Elaine Spalding12, Peter C. Thomson5, Patrick B. Mark5, Jamie P. Traynor2,5 and on behalf of the
Scottish Renal Registry
Abstract
Background: Infection with the severe acute respiratory coronavirus 2 (SARS-CoV-2) has led to a worldwide
pandemic with coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2, overwhelming healthcare
systems globally. Preliminary reports suggest a high incidence of infection and mortality with SARS-CoV-2 in
patients receiving kidney replacement therapy (KRT). The aims of this study are to report characteristics, rates and
outcomes of all patients affected by infection with SARS-CoV-2 undergoing KRT in Scotland.
Methods: Study design was an observational cohort study. Data were linked between the Scottish Renal Registry,
Health Protection Scotland and the Scottish Intensive Care Society Audit Group national data sets using a unique
patient identifier (Community Health Index (CHI)) for each individual by the Public Health and Intelligence unit of
Public Health, Scotland. Descriptive statistics and survival analyses were performed.
Results: During the period 1st March 2020 to 31st May 2020, 110 patients receiving KRT tested positive for SARS-CoV-2
amounting to 2% of the prevalent KRT population. Of those affected, 86 were receiving haemodialysis or peritoneal
dialysis and 24 had a renal transplant. Patients who tested positive were older and more likely to reside in more
deprived postcodes. Mortality was high at 26.7% in the dialysis patients and 29.2% in the transplant patients.
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Conclusion: The rate of detected SARS-CoV-2 in people receiving KRT in Scotland was relatively low but with a
high mortality for those demonstrating infection. Although impossible to confirm, it appears that the measures
taken within dialysis units coupled with the national shielding policy, have been effective in protecting this
population from infection.
Keywords: COVID-19, Kidney replacement therapy, Epidemiology, Registry
Background
Infection with the severe acute respiratory coronavirus 2
(SARS-CoV-2) has led to a worldwide pandemic with
COVID-19, the disease caused by SARS-CoV-2, over-
whelming healthcare systems globally [1]. The clinical
course of the disease varies significantly from asymptomatic
disease to multi-organ failure and death [2]. Patients receiv-
ing kidney replacement therapy (KRT) are a vulnerable
population as those receiving dialysis are usually older with
significant co-morbidity, have impaired immune responses
[3] and require regular attendance at a healthcare facility
which further increases their risk of exposure. Patients who
have a kidney transplant are presumed to be at high risk
due to their obligate immunosuppressive medications.
There have been a number of published recommendations
on how to mitigate spread of SARS-CoV-2 in dialysis units
[4–8]. There is, however, a lack of data regarding clinical
course and outcome in patients receiving KRT following
infection with SARS-CoV-2. Furthermore, early reports
suggest that case fatality in dialysis patients if infected is
high with reports suggesting fatality in the order of 5–20%
compared to 1–2% in patients not requiring KRT [9–11].
Patients requiring KRT often have multiple comorbid con-
ditions which are widely documented as increasing the risk
of death from COVID-19 such as older age, chronic condi-
tions such as diabetes mellitus and hypertension [12, 13]
but may be at additional risk due to the relatively impaired
immune response associated with kidney failure.
The first case of SARS-CoV-2 infection in Scotland
was confirmed on 1st March 2020, although subsequent
data suggest that the virus had been in circulation for
weeks prior to this [14]. On 24th March, as part of the
Scottish Government response to the pandemic, certain
groups of patients were identified as the most vulnerable
to developing severe illness and advised to “shield”
meaning they were advised to remain at home and
minimise all non-essential contact with other members
of their household. This “shielded” category included
kidney transplant recipients (KTR) from the outset but
Scottish (and United Kingdom) government advice was
not applied to dialysis patients until 28th April 2020.
However, most renal units commenced implementation
of PPE protocols prior to government advice. Delivering
care to these patients whilst minimising risk of exposure
and preventing transmission of infection to these vulnerable
patient groups posed significant challenges to renal units
across the country.
The aims of this study are to report characteristics,
rates and outcomes of all patients affected by infection
with SARS-CoV-2 undergoing chronic KRT including
KTRs in Scotland.
Methods
Data sources
Study design was an observational cohort study. The
following national data sets were linked using a unique
patient identifier (Community Health Index (CHI)) for
each individual by Public Health and Intelligence unit of
Public Health, Scotland. The Scottish Renal Registry is a
national registry of all patients receiving KRT for end
stage renal disease (ESRD) in Scotland (haemodialysis,
peritoneal dialysis and transplant). It was established in
1991 with data backfilled to 1960 from European Renal
Association-European Dialysis and Transplant Associ-
ation (ERA-EDTA) with the first patient dialysed for
ESRD in Scotland in 1960. The Scottish Renal Registry
has 100% unit and patient coverage. Data held by the
registry include patient demographics including histor-
ical postcodes (for calculating Scottish Index of Multiple
Deprivation), full KRT history (for ESRD), date and
cause of death (using ERA-EDTA codes), primary renal
diagnosis (using ERA-EDTA codes) and monthly linkage
with National Health Service Blood and Transplant
(NHS BT) for transplant status. The primary renal diag-
nosis groupings used in the analyses is described in the
Scottish Renal Registry website [15]. The Scottish
Government provide online calculators allowing use of
patient postcode to generate divisions of socioeconomic
deprivation, the Scottish Index of Multiple Deprivation
(SIMD) [16]. Using patient postcode, deprivation quin-
tiles were calculated and categorized into most deprived
quintiles with 1 corresponding to most deprived and 5
as least deprived. Data on testing for COVID-19 were
obtained from Health Protection Scotland with date of
test and result reported. Data on admission to intensive
care units were obtained from the Scottish Intensive
Care Society Audit Group (SICSAG). The Scottish
Intensive Care Society Audit Group (SICSAG) has main-
tained a national database of patients admitted to adult
general Intensive Care Units (ICU) in Scotland since
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1995 [17]. Detailed information is produced on the man-
agement of critically ill or injured patients. All general
intensive care units (ICU) and combined ICU/high de-
pendency units (HDU) collect data. During this period,
there was no limitation of access to ICU admission for
patients with comorbid conditions, with patients admit-
ted to ICU if clinicians felt it was clinically appropriate.
Testing for SARS-CoV-2 was carried out by real-time
polymerase chain reaction (RT-PCR) on a combined
nasal and pharyngeal throat swab only in symptomatic
patients or endotracheal aspirate for those ventilated in
ICU. If a patient has been tested multiple times, the date
of the first positive or first negative test was used. If a
patient has tested positive, then subsequently tested
negative they would only appear in the positive cohort.
Statistical analysis
Data were linked and analysed by a Public Health
Intelligence analyst at Public Health Scotland. Baseline
characteristics were displayed as mean and standard
deviation (SD) or median and interquartile range (IQR)
for continuous variables depending on normality. T-tests
and chi-squared tests were utilised to examine differ-
ences in parameters between those who died and those
were still alive as of 31st May 2020. Categorical variables
were displayed as number and percentage. Logistic
regression was performed with SARS-Cov-2 positivity as
a binary outcome. Crude survival was measured at 30
days since first SARS-Cov-2 test using Kaplan Meier
survival analyses. Cox proportional hazards models were
performed to examine predictors of death. All analyses
were performed using R Studio 3.5.1 [18].
Results
Scottish Renal Registry
The Scottish renal registry collates data from all 9 adult
renal units in Scotland and 28 satellite haemodialysis
units (Fig. 1) serving a population of 5.4 million. On 31st
May 2020, there were 5475 prevalent patients in
Scotland receiving KRT. Of these, 1983 were on haemo-
dialysis with 206 peritoneal dialysis and 3286 with func-
tioning kidney transplants.
Characteristics of SARS-CoV-2 positive patients
As of 31st May 2020, 876 patients receiving KRT had
been tested for SARS-CoV-2 infection. This represents
16% of the total number of 5475 receiving KRT on 31st
May 2020. One hundred and ten were positive which
amounts to 2% of the prevalent KRT population. Of
those affected, 86 were receiving haemodialysis or peri-
toneal dialysis and 24 had a renal transplant. Figure 2
shows the distribution of those individuals who tested
positive for SARS-CoV-2 by geographical location rela-
tive to the whole KRT population. In keeping with the
national figures related to the general population, the
majority of positive tests were within the central belt of
Scotland. Figure 3a shows the number of positive cases
by week with a peak in positive cases between the 30th
of March and 13th of April. This contrasts with data for
general population across Scotland where the number of
new cases only started to fall during week beginning
27th April (Fig. 3b). There were 986 tests performed in
876 patients until the 31st May with 110 (11.2%) testing
positive. The cumulative number tested and the propor-
tion of positive cases over time is shown in Figs. 4a and
b with a sharp increase in testing over the time period
examined. Characteristics of the kidney replacement
population and those who tested positive for SARS-
CoV-2 are shown in Table 1. Mean age of those tested
positive was 64.3 years old (SD 14.4) with a primary
renal diagnosis of diabetes in 33.7% and median dialysis
vintage of 4 years (IQR 1–8 years). Of the 24 patients
who had a functioning kidney transplant when tested
positive for SARS-CoV-2, the majority of the transplants
(n = 14) were performed over 10 years ago with 8% (n =
2) cases recorded had a transplant less than 2 years ago.
65% of those who tested positive lived in the most
deprived areas (SIMD 1 or 2). 98 of 110 who tested
positive were of white ethnicity. We do not have data on
the ethnicity of the entire KRT population. Using logistic
regression, increasing age at time of infection OR 1.038
(95%CI 1.023–1.053), p < 0.001 and social deprivation
OR 0.778 (95% CI 0.673–0.899), p = 0.001 (with every
quintile increase in in SIMD) were predictors of testing
positive for all those on KRT on 31 May 2020 registered
on the SRR.
Patient outcomes
As of the 31st May 2020, 30 (28.2%) of the patients who
tested positive for SARS-CoV-2 infection died. Twenty
three (26.7%) of the 86 patients treated with haemodialy-
sis or peritoneal dialysis who tested positive died. Seven
(29.2%) of the 24 transplant patients who tested positive
died. Mean age of death was higher in those who died
compared with those who were still alive as of 31st May
2020 (69 years (SD 11.6) vs. 62 years (SD 8.5), p =
0.0182). There was no difference in median dialysis vin-
tage of those who died compared with those who were
still alive as of 31st May 2020: 4 years (IQR 1–12 years)
vs 4 years (IQR 1–7 years, p = 0.34). One third of patients
who died had a primary renal diagnosis of diabetic
nephropathy. Figure 5 shows the total number of deaths
in the KRT therapy population in Scotland from 1st
January 2020 to 31st May 2020 with those who had
COVID-19 identified as a primary cause of death on the
death certificate. Figure 6 shows the number of deaths
from 1st January to 31st May each year from 2017 to
2020. Deaths in 2020 not related to COVID-19 are also
Bell et al. BMC Nephrology          (2020) 21:419 Page 3 of 12
shown. Both Figs. 5 and 6 demonstrate an increase in
deaths occurring in April compared with other months.
Figure 5 in particular highlights that a large proportion
(35%) of the deaths occurring in April were related to
COVID-19. Crude thirty day survival is shown in Fig. 7a
and b. There was 91% (95% CI 89–94) 30 day survival in
those to tested negative compared with 71% (95% CI
63–80) 30 day survival in those who tested positive.
Increasing age was associated with mortality in cox
proportional hazards model with an increase of hazard
ratios for death of 1.028 (95% CI 1.001 to 1.055, p =
0.038) for every year of age.
Intensive care admission
During the period from 1st March 2020 to 31st May
2020 there were a total of 118 patients registered on the
SRR who were admitted to an ICU/HDU in Scotland. Of
these 13 (13%) patients had tested positive for SARS-
CoV-2 infection. 92.3% of those with SARS-CoV-2 were
discharged alive from ICU compared with 94.1% who
were not tested/tested negative. However, of those who
were discharged alive from ICU/HDU 41.6% of those
with a positive SARS-CoV-2 test died within 7 days of
being discharged compared to 6.94% of those who did
not have a positive test result. Details of ICU/ HDU ad-
mission are shown in Table 2.
Discussion
As of May 31st 2020, SARS-CoV-2 was detected in 2%
of the prevalent Scottish KRT population (3.9% of the
prevalent dialysis population and 0.7% of the prevalent
transplant population). Mortality was high at 26.7% in
the dialysis patients and 29.2% in the transplant patients.
Patients who tested positive were more likely to be older
and from more deprived postcodes. Increasing age was
associated with mortality.
During the early stages of the pandemic, advice about
personal protective equipment (PPE) was subject to a
number of changes mainly in response to guidance is-
sued by UK government for use of PPE in the healthcare
environment. On 2nd April 2020, the UK and Scottish
governments issued new PPE guidelines for patients and
staff in secondary care and these in turn informed the
UK Renal Association recommendations for PPE in
dialysis units [8, 19]. The guidance has largely remained
unchanged since and essentially advocates that staff use
face masks (one per session) and single use aprons and
gloves with all patients, including those where COVID
was not suspected. After discussion with local
Fig. 1 Dialysis Locations in Scotland (own figure). ARI Aberdeen Royal Infirmary, XH Crosshouse Hospital, DGRI Dumfries and Galloway Royal
Infirmary, GLAS Glasgow Royal Infirmary, MONK Monklands Hospital, NINE Ninewells Hospital Dundee, RAIG Raigmore Hospital Inverness, RIE Royal
Infirmary of Edinburgh, VHK Victoria Hospital Kirkcaldy
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microbiology/infectious disease/infection control teams,
most units implemented these changes in renal dialysis
units very quickly with all units following this guidance by
6th April 2020. Two units adopted this approach before
the government advice with the earliest adoption of PPE
on 13th March 2020.
All dialysis patients now wear a mask for travelling into
dialysis and during the session. Patients are given a mask to
use for next session. Patients are advised to minimise time
spent eating or drinking i.e. time with mask off. Waiting
areas are a potential challenge as in some units these are
very small and cannot facilitate adequate social distancing.
Approaches to address this includes staggering start times
for dialysis and asking patients to wait in their transport ve-
hicle until the staff are ready to commence their dialysis
session. All patients have individual transport except a few
cases where following an adequate risk assessment, two pa-
tients share an ambulance but wear masks. Individualised
transport has only been possible whilst there is reduced de-
mand from other specialties which have put non-essential
services on hold or at significant cost to the units by provid-
ing single occupancy taxi for transport. Most units have, or
are actively making plans for, the time when individual
transport is no longer available or manageable. All units
measure patient temperature on arrival. The threshold for
action varies between temperature of 37.8o and 38.0o de-
grees with the exception of one satellite unit which has a
threshold of 37.0o. Once reached, this threshold triggers
testing for SARS-COV2 and dialysis in isolation. All units
have taken measures to minimise visits to hospital for
people with a functioning transplant. Clinical records are
reviewed in advance of clinics. Unless a face-to-face con-
sultation is considered necessary, alternative options have
included telephone consultations, blood tests only and
increased time between clinics. Phone consultations
are provided mostly by medical staff but some units
include transplant nurse specialists. Bloods have been
taken in a variety of settings including newly set up
‘bloods only’ clinics, bespoke mobile phlebotomy ser-
vice, existing community hubs or in coordination with
primary care.
There is currently a lack of data on how SARS-CoV-2
affects patients receiving haemodialysis. Early reports
from Wuhan suggested a milder disease in these patients
[20]. However, more recent reports are suggesting worse
outcomes. The Lombardy and Brescia regions of Italy
were severely affected by COVID-19. An observational
study from 4 dialysis centres in the Brescia region of
Italy showed that 95 (15%) of 643 haemodialysis patients
tested positive for COVID-19 with 27 (29%) of these dying
[21]. A further observational study from a haemodialysis
centre in Spain found that 36 patients out of 282 patients
tested positive for COVID-19 and 11 (30.5%) of these pa-
tients subsequently died. Dialysis vintage was associated
with mortality in this cohort of patients [22]. Similarly, a
study of 59 consecutive patients testing positive from
Columbia University in the United States found a mortality
rate of 31% (18 patients) [11]. A report from the COVID-
19 registry of the Spanish Society of Nephrology reported a
mortality of 23% in 868 patients with SARS-CoV-2
Fig. 2 Geographical output of SARS-CoV-2 in KRT patients up to 31 May 2020 (own figure)
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infection. Mortality was associated with increasing age in
this cohort [23]. A study from a single urban centre in the
United Kingdom showed much higher rates of trans-
mission with over 20% of their haemodialysis patients
affected within 6 weeks of detection of their first case
[24]. Similar mortality rates was demonstrated in this
series with 20.3% patients dying during follow up,
again with increasing age being associated with higher
Fig. 3 a: Number of patients* on KRT who tested positive for SARS-CoV-2. *If a patient has been tested multiple times, the date of the first
positive or first negative test was used. If a patient has tested positive, then subsequently tested negative they would only appear in the positive
cohort. b: Number of patients in Scotland who tested positive for SARS-CoV-2
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likelihood of mortality. The outcomes we report in kidney
transplant recipients with 29.2% of those with COVID-19
dying is similar to that reported in New York [25]. The
number of patients in our cohort who required intensive
care is perhaps lower than might be expected. However,
within renal units, detection of SARS-COV2 triggered
treatment escalation planning. This included discussion
with patients about appropriate and realistic ceilings of
treatment. As a result the number of people referred to
ICU will have been reduced.
Fig. 4 a: Cumulative number of SRR patients* on KRT with a SARS-CoV-2 test. b: Cumulative number of SRR patients* on KRT with a SARS-CoV-2
test split by modality. c: Cumulative number of patients in Scotland with a SARS-CoV-2 test (Source: http://www.gov.scot/publications/coronavirus-
covid-19-trends-in-daily-data/)
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In the general population, a number of comorbid con-
ditions such as diabetes, hypertension and obesity have
consistently been linked to increased risk of death with
COVID-19 [12]. In patients requiring KRT, it is clear
that the risk attributable to requirement for KRT is such
a strong risk factor for death that it is challenging to
identify subgroups of dialysis or kidney transplant recipi-
ents at highest risk.
Table 1 Descriptive characteristics of all prevalent patients undergoing KRT in Scotland on 31st May 2020
Dialysis Transplant
COVID-19 +
n = 86
Total on HD & PD
n = 2184
COVID-19 +
n = 24
Total Transplant
n = 3277
n (%) n (%) n (%) n (%)
Sex Female 39 (45) 879 (40) 11 (46) 1318 (40)
Male 47 (55) 1305 (60) 13 (54) 1959 (60)
Age Group 20–44 10 (12) 244 (11) 4 (17) 774 (24)
45–64 25 (29) 829 (38) 12 (50) 1745 (53)
65–74 24 (28) 599 (27) 5 (21) 612 (19)
75+ 27 (31) 512 (23) 3 (13) 146 (4)
Primary Renal Diagnosis Glomerulonephritis 14 (16) 374 (17) 3 (13) 851 (26)
Interstitial 20 (23) 464 (21) 12 (50) 1275 (39)
Multisystem 15 (17) 489 (22) 3 (13) 386 (12)
Diabetes 29 (34) 569 (26) 3 (13) 386 (12)
Unknown 8 (9) 288 (13) 3 (13) 379 (12)
aDialysis Vintage < 1 year 20 (23) 444 (20) 0 (0) 310 (9)
1–2 years 14 (16) 349 (16) 2 (8) 314 (10)
2–3 years 8 (9) 293 (13) 1 (4) 339 (10)
<= 5 years 22 (26) 468 (21) 3 (13) 698 (21)
<=10 years 11 (13) 243 (11) 4 (17) 701 (21)
> 10 years 11 (13) 301 (14) 14 (58) 88 (27)
SIMD 1 =most deprived 32 (37) 634 (29) 7 (29) 715 (22)
2 24 (28) 503 (23) 5 (21) 698 (21)
3 10 (12) 417 (19) 4 (17) 631 (19)
4 13 (15) 356 (16) 5 (21) 646 (20)
5 = least deprived 7 (8) 274 (13) 3 (13) 587 (18)
Patients with missing data (n = 14) not included in total for analysis purposes - none of which were COVID-19 +
aDialysis vintage for those on transplant is taken from the date of the transplant, those on dialysis is their time on KRT
Fig. 5 Number of Deaths in KRT population per calendar month. *For all those patients who tested positive for SARS-CoV-2 – all had SARS-CoV-2
as Cause of Death on death certificate
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SARS-CoV-2 has affected a relatively small proportion
of the KRT patients in Scotland. However, mortality was
high in those affected and COVID-19 has been associ-
ated with excess mortality in the KRT population of
Scotland during this period compared to equivalent pe-
riods during previous years. Renal unit staff and trans-
port services have worked hard to mitigate and contain
transmission within the individual dialysis and satellite
units. The subsequent drop in new cases by the third
week of April suggests that these measures coupled with
shielding were effective. It is not possible to say with ab-
solute certainty but the experience in a large dialysis unit
in London has led to similar conclusions [24]. Infection
control measures are likely to have been beneficial in re-
ducing transmission associated with dialysis treatment,
either related to transport with other patients, or during
treatment itself. However, it is not possible to dissociate
the reduction in number of cases of SARS-CoV-2 in the
KRT population from the fall observed in the general
population in response to measures encompassed by
‘lockdown’ including closure of schools and non-
essential shops, increased hand hygiene and social dis-
tancing. However, as the incidence of new SARS-CoV-2
infections specifically in patients on KRT fell prior to
any fall in the incidence of SARS-CoV-2 in Scotland
(Fig. 3), it is plausible that the combination of measures
specific to this high risk group had efficacy in driving
down new infections, rather than to simply assume that
falling infection in KRT patients reflected reducing
community transmission of SARS-CoV-2. It is worth
noting that highest numbers of SARS-CoV-2 infection
was observed in patients residing in areas of highest
socioeconomic deprivation. Although the numbers of
infections do not necessarily track to outcomes, most
UK and Scotland data demonstrate that infection rates
and deaths with SARS-CoV-2 are higher in areas of
socioeconomic deprivation [26].
A strength of our study is that we have comprehensive
coverage of all patients receiving KRT in Scotland with
linkage to Health Protection Scotland which holds data
on all testing for SARS-CoV-2 performed in Scotland.
However, limitations of our study are that we did not
have data on hospitalisations, co-morbidities, immuno-
suppression regimes, acute kidney injury or smoking sta-
tus. Fortunately, our numbers were small. However, this
limits our ability to draw conclusions from our analyses.
Only symptomatic patients were tested, so we cannot
comment on the asymptomatic rate of SARS-CoV-2 in-
fection, this may have led to lower case ascertainment in
the population of patients with kidney transplants. How-
ever, unlike in the wider UK population, testing was
performed liberally, and to the best of our knowledge in
all symptomatic patients requiring dialysis and in those
without symptoms but who presented with fever.
Conclusion
In summary, we demonstrate that 2% of the KRT popula-
tion had a positive test for SARS-CoV-2 during the period
of study. The incidence of positive tests fell following insti-
gation of infection control measures. Mortality is high and
it is unclear if any of the therapies demonstrated to im-
prove outcomes in patients with COVID-19 such as dexa-
methasone or remdesivir will have efficacy in patients
requiring KRT. Patients requiring dialysis were excluded
from recent remdesivir trials [27]. It is likely that in the
absence of specific therapy, and high mortality, heightened
vigilance of the risk of SARS-CoV-2 infection, infection
control measures including use of PPE for both staff and
Fig. 6 Number of deaths in KRT population – comparison over multiple years. *This lines shows the number of deaths after removing those
cases where SARS-CoV-2 was the Cause of Death
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Fig. 7 a: Survival at 30 days from first SARS-CoV-2 test. *Log Rank Test for KM is p < 0.001. Survival at 30 days: SARS-CoV-2 Neg: 0.91 (95% CI
0.894,0.94); SARS-CoV-2 Positive: 0.71 (95% CI 0.630, 0.802). b: Survival at 30 days from first SARS-CoV-2 Test split by modality at time of test result.
Survival at 30 days Haemodialysis: SARS-CoV-2 Neg: 0.92 (95% CI 0.885, 0.94); SARS-CoV-2 Positive: 0.71 (95% CI 0.623, 0.817). Survival at 30 days
Kidney Transplant: SARS-CoV-2 Neg: 0.94 (95% CI 0.91, 0.98); SARS-CoV-2 Positive: 0.71 (95% CI 0.544, 0.915)
Table 2 Details of ICU/ HDU admission
COVID-19 Positive COVID-19 Negative Not Tested Total of SRR Patients
Number of patients with ICU/HDU stay 13 77 28 118
Median Length of Stay 6.0 4.0 3.0 4.0
Average Advanced Ventilation Days 2.6 0.7 0.1 0.8
Average Non Invasive Ventilation Days 0.5 0.2 0.0 0.2
Average Cardio Support Days 1.4 0.7 0.2 0.7
Average Renal Support Days 2.8 2.1 0.5 1.8
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patients, will be required for the long term to mitigate the
risk of SARS-CoV-2 in this vulnerable patient group. This
may come at a cost of increasing social isolation and more
limited social interaction between other patients, health
care workers and wider society. Moreover, the economic
cost of providing additional transport for individual pa-
tients travelling to dialysis, more dedicated nursing staff
and segregated dialysis bays, as well as for additional PPE
will add substantially to the existing financial burden of
KRT to healthcare systems.
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